Ocuvex Therapeutics

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (NDA 217363, letter dated May 15, 2026). FDA NDA 217363 (May 15, 2026)
  Evidence (1 event)

  • May 15, 2026 · FDA NDA 217363
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Ocuvex Therapeutics, Inc. Attention: Anthony Amato Chief Executive Officer Lee, NJ (street omitted) Dear Anthony Amato: Please refer to your new drug applicati

Job counts as of Oct 18, 2026. All trial and FDA signals